Balanced news tone
News Sentiment
ALXO sentiment intelligence
Alx Oncology Holdings news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
34 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+2.7% over one week, +34.5% over four weeks, trend active, and below fair value.
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
2.7%
Price confirming higher
Trend fit
Trend active
34.5% over four weeks
Fair value
-52.2%
Below fair value
Market Dynamics buy signal
Value support
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
30
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Titan
Direct company coverage
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
MT Newswires
Direct company coverage
ALX Oncology Appoints Scott Garland as Board Chairman
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 12:23
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 12:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
ALX Oncology grants 500,000-share option to new general counsel
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
ALX Oncology replaces its chairman and adds a new general counsel
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
marketscreener.com
Direct company coverage
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 12:14
- Source
- marketscreener.com
The Globe and Mail
Direct company coverage
ALX Oncology Secures New $50 Million Loan Facility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:00
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Seeking Alpha
Direct company coverage
ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Seeking Alpha
Stock Titan
Direct company coverage
ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Stock Titan
simplywall.st
Direct company coverage
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- simplywall.st
MarketBeat
Direct company coverage
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 03:02
- Source
- MarketBeat
Motley Fool
Direct company coverage
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jun 2026 17:23
- Source
- Motley Fool
GlobeNewswire
Direct company coverage
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:00
- Source
- GlobeNewswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Moby
Direct company coverage
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 May 2026 12:30
- Source
- Moby
MarketBeat
Direct company coverage
ALX Oncology Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 14:57
- Source
- MarketBeat
Quiver Quantitative
Direct company coverage
ALX ONCOLOGY ($ALXO) Releases Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- Quiver Quantitative
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Investing News Network
Direct company coverage
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Investing News Network
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Investing.com
Direct company coverage
Wells Fargo initiates ALX Oncology stock with overweight rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 19 Mar 2026 07:00
- Source
- Investing.com
Seeking Alpha
Direct company coverage
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Mar 2026 08:00
- Source
- Seeking Alpha